Valgancyclovir as maintenance therapy for cytomegalovirus retinitis in a lung transplant patient--a case report.
The purpose of this article is to report the use of valgancyclovir as maintenance therapy for cytomegalovirus (CMV) retinitis in a lung transplanted patient.


RESULTS
A 30-year-old woman with underlying pulmonary lymphangioleiomyomatosis received a lung transplant 1 year ago. CMV retinitis developed 4 months later but subsided after intravenous ganciclovir treatment. Unfortunately, the CMV retinitis recurred three times in 1 year while on oral ganciclovir maintenance therapy. To treat the latest relapse, valgancyclovir 900 mg once daily was used as maintenance therapy after intravenous gancyclovir induction. With a 6-month follow-up, the fundoscopic examination revealed old atrophic scar and no active CMV retinits. The patient was able to maintain best-corrected visual acuity of 20/20 in both eyes. In conclusion, Valganciclovir may be used as maintenance therapy in CMV retinitis.
Wang
T-J
TJ
Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
Lin
C-P
CP
Yang
C-M
CM
Lin
L L-K
LL
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D005260:Female; D005654:Fundus Oculi; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D016040:Lung Transplantation / Q000502:physiology*; D011183:Postoperative Complications / Q000188:drug therapy; D000077562:Valganciclovir
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir